Regenerative Medicine Research for Erectile Dysfunction: Evidence and Regulation in Japan
This page examines published human research, evidence limitations and Japan’s regulatory framework. It does not describe a service offered by Japan Medical.
Current Status at a Glance
Four conclusions frame everything that follows; each is developed below with sources.
Evidence remains limited and heterogeneous
Human research on cell-based ED interventions is still small in volume and varied in design, cell source, dose and patient group. Reviews of this literature describe the overall certainty as low, so findings cannot yet be generalized across settings.[1]
Early studies measured change from baseline
Initial open-label studies reported that some participants’ scores changed after treatment. Because these studies had no comparison group, such changes cannot establish that the intervention caused them.[2]
The strongest test found no advantage
The 2026 randomized double-blind placebo-controlled study did not demonstrate a significant advantage over placebo for the outcomes and population examined.[3]
What Erectile Dysfunction Means
Erectile dysfunction (ED) means persistent difficulty getting or keeping an erection firm enough for sexual activity. It becomes more common with age and is frequently linked to an underlying factor — vascular, neural, hormonal, psychological or medication-related — rather than existing as an isolated problem.[6] Researchers are studying whether cellular mechanisms may influence vascular, neural or tissue-related pathways. These hypotheses do not establish clinical benefit.[6]
Why Medical Evaluation May Matter
Because ED often reflects an underlying condition, a professional evaluation can change the entire direction of care. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases, an evaluation for ED may involve a medical history, a medication history, a sexual and mental health history, and a physical examination, with laboratory or other testing where appropriate.[7] The purpose is to identify treatable causes — for example an undiagnosed vascular or hormonal problem — and to review whether current medicines may contribute. This page does not provide self-diagnosis steps, test thresholds or individual recommendations; those depend on personal circumstances and are matters for an individual’s own doctor.[7]
Established Approaches and Where Research Fits
Established approaches include addressing underlying factors, lifestyle measures, counselling, oral medicines, vacuum devices, injected medicines and surgery. Suitability and response vary according to cause, medical history and individual circumstances.[8] Cell-based interventions are not part of this established list. They appear in the literature as study interventions, and health authorities generally direct people considering them toward regulated clinical trials rather than commercial offers.[8][9]
Where Regenerative Research Fits
Regenerative medicine studies whether cells or cell-derived signals can support repair in damaged tissue. For ED, this remains a research question pursued inside clinical studies — not an established treatment category. Both the U.S. Food and Drug Administration and the International Society for Stem Cell Research caution that most cell-based interventions marketed directly to consumers have not been proven effective through rigorous trials.[9][10]
Inside research settings
Legitimate studies are registered in advance, define their participants and outcomes before starting, obtain ethics review and publish results whether positive or negative. Registries let anyone check whether a study exists and what it measured.[10]
Consumer-protection guidance
Regulators advise skepticism toward interventions sold with strong outcome promises but without controlled-trial support. An investigational status means a question is still being studied; it is not a preliminary verdict that the answer is yes.[9]
Cell Sources Are Not Interchangeable
“Stem-cell therapy for ED” describes many different products and procedures. The source of the cells, how they are prepared and who receives them all differ between studies — and the differences matter when reading results.[11]
Results from one cell source, preparation method or patient population cannot automatically be applied to another. A finding about donor cord cells in diabetic ED does not describe what a patient’s own fat-derived cells might do after prostate surgery.[11]
Proposed Mechanisms: Preclinical Context Only
Most mechanistic understanding comes from laboratory and animal research, not from demonstrated human benefit. Reviews describe four recurring hypotheses; none, by itself, is evidence that a treatment works in people.[11]
Chemical signalling
Cells release growth factors and signalling molecules that, in preclinical models, appeared to encourage local repair processes.[11]
Blood-vessel support
Animal studies observed the formation of small new vessels after cell administration — relevant because erection depends on rapid blood flow.[11]
Nerve-repair support
Preclinical work suggested cell signalling may support recovery of nerves injured during pelvic surgery; human confirmation is lacking.[11]
Anti-scarring effects
Laboratory studies indicated cell-derived signals may reduce fibrosis and inflammation in erectile tissue models.[11]
How to Read the Evidence Hierarchy
Not all study designs answer the same question. The table below summarizes what each common design can and cannot show.
| Design or record | What it is | What it can show | What it cannot show |
|---|---|---|---|
| Phase I study | Small first-in-human study | Initial safety signals and feasibility | Whether the intervention works[10] |
| Open-label study | Everyone knows which treatment is given | Change from each participant’s starting point | That the intervention caused the change[1] |
| Randomized controlled trial | Chance assigns participants to intervention or control | Whether the intervention outperforms the control | Results beyond the studied population and protocol[3] |
| Systematic review / meta-analysis | Structured summary and statistical pooling of studies | The pattern across a body of literature | More certainty than the included studies contain[1] |
| Trial registry | Public record of a study’s plan and status | That a study exists and what it intends to measure | Approval, effectiveness or safety of the intervention[14] |
Understanding the Outcome Measures
ED studies report scores and device measurements. Knowing what each one captures prevents over-reading a single number. A change in a score is a measurement result; this page does not describe score changes as “recovery”.[1]
Human Studies at a Glance
This page summarizes the human studies identified through the source-search method described below. The table lists each study’s design, cells, participants, reported findings and limits, so that no result appears without its context.
| Study | Design | Cells & participants | Reported findings | Limits |
|---|---|---|---|---|
| Haahr 2016Denmark [2] | Phase I, open-label | Own fat-derived cells · 17 men, post-prostate-surgery ED | Eight of 17 participants met the functional threshold reported by the study at six months. Because the study had no control group, the observed change cannot be attributed to the intervention. | Small; single centre; one cause of ED |
| Haahr 2018Denmark [16] | 12-month follow-up | Same cell type · 21 men, post-surgery ED | No serious cell-related adverse events were reported during the follow-up period. | Safety-focused; no control group; small |
| You 2021South Korea [12] | Phase I, open-label | Own bone-marrow cells · 10 men, post-surgery or diabetic ED | Mean IIEF score changed from 18.1 to 24.9 at one month; reported adverse events were judged unrelated to the cells. | Very short observation window; authors called for phase 2 confirmation |
| Al Demour 2021Jordan [13] | Phase 1/2, open-label | Donor umbilical-cord cells · 22 men, diabetic ED | Scores and measured blood-flow velocity changed from baseline over 12 months; transient bruising was reported. | No control group; single centre |
| Al Demour 2024Jordan [17] | Phase 2, open-label | Own bone-marrow cells · 8 men, diabetic ED | Reported changes from baseline held through 12 months, then declined significantly by 24 months. | Very small group; durability uncertain; repeat dosing untested |
| Senel 2025Meta-analysis [1] | 11 studies reviewed, 6 pooled | Various cell types · pooled early-phase data | Pooled scores showed change from baseline at six months across function, hardness and blood-flow measures. | Included studies small and varied; longest pooled follow-up six months |
| Hansen 2026Denmark [3] | Randomized, double-blind, controlled | Own fat-derived cells vs placebo · 70 men, post-surgery ED | No significant between-group difference on the primary outcome or secondary measures at 12 months. | Findings apply to this population, preparation and protocol |
One pattern stands out
The 2026 Placebo-Controlled Trial
The most rigorous study published so far deserves a close reading, because it is the only one in this field designed to separate the intervention’s effect from everything else.[3]
Study record
Design and participants. A randomized, double-blind, placebo-controlled trial enrolled 70 participants with ED following radical prostatectomy at a single university centre. Thirty-five received one injection of their own adipose-derived regenerative cells and 35 received a placebo; neither participants nor assessors knew the assignments. The primary outcome was the change in IIEF-5 score at 12 months versus baseline; secondary outcomes included the Erection Hardness Scale and RigiScan device measurements at 6 months.[3]
Results. The primary outcome showed no significant difference between groups (IIEF-5, p > 0.99), and the hardness scale likewise showed none (EHS, p = 0.85). RigiScan measurements showed no significant overall advantage for the cell group. No severe adverse events were reported during the study period. The study was not designed or sized to establish comprehensive or long-term safety.[3]
Interpretation. The study did not demonstrate a significant advantage over placebo for the outcomes and population examined. The authors stated that the intervention, in its current form, cannot be recommended for that population. Its findings have limited generalizability to other patient groups, other cell preparations and other protocols.[3]
Why the Meta-analysis and RCT Appear Different
A 2025 meta-analysis reported pooled improvements at six months, while the 2026 controlled trial found no between-group advantage. These results sit in tension but are not necessarily contradictory, because they answer different questions.[1][3]
Different questions
Earlier studies mainly examined change from baseline, while the placebo-controlled trial examined whether the intervention performed better than placebo. Both statements can be accurate at the same time.[1][3]
Different inputs
The meta-analysis pooled small, mostly uncontrolled studies with varied methods, and reported heterogeneity from low to high. A pooled average cannot exceed the certainty of its inputs.[1]
What the tension means
The controlled result raises the possibility that earlier changes reflected factors other than the cells — but this page does not claim the earlier results were entirely expectation effects. The correct reading is that uncertainty increased.[3]
What would resolve it
Additional independent randomized trials, across causes of ED and cell types, with pre-registered outcomes and longer follow-up. Several studies are listed in public registries.[15]
What Safety Data Do — and Do Not — Show
Safety reporting in this literature is reassuring in tone but narrow in scope. The two sides below should be read together.[3][17]
Small studies cannot rule out rare harms. A trial of dozens of participants can describe common, immediate effects, but detecting uncommon or delayed harms requires far larger and longer observation than this literature currently offers.[9]
What Remains Unknown
Even if future controlled trials show a benefit, the following questions would still need answers before any cell-based approach could be considered established for ED.[1][11]
Optimal cell sourceFat, bone marrow, cord tissue or another source — no comparative human data exist.[11]
DoseCell numbers varied widely between studies; no dose-finding trials have been published.[1]
Number of administrationsStudies used one or two injections; whether more would help or harm is untested.[17]
Patient selectionWhich causes of ED, if any, might respond remains undefined.[3]
DurabilityOne small study observed declines by 24 months; long-term trajectories are unmapped.[17]
Clinically meaningful benefitWhether any change is large enough to matter in daily life is unanswered.[1]
Long-term adverse eventsFollow-up beyond two years does not exist in this literature.[17]
Applicability across causesEvidence covers post-surgical and diabetic ED only; other causes are unstudied.[3]
Interaction with established approachesWhether cell-based methods combine with medicines or devices — safely or usefully — is unknown.[8]
Manufacturing consistencyPreparation methods differ between laboratories; standardization data are limited.[11]
Japan Has Two Different Regulatory Routes
Japan has invested unusually deeply in this field — the reprogramming technique behind iPS cells was developed there and recognized with the 2012 Nobel Prize in Physiology or Medicine.[18] For readers, the practical point is that Japan regulates cell-based interventions through two separate legal routes, and they mean different things.[4][19]
Route one: providing an intervention
The Act on the Safety of Regenerative Medicine governs provision of a cell-based intervention as a medical practice: plans, certified-committee review and facility standards.[4]
Route two: product approval
The PMD Act covers marketing approval of a regenerative medical product, including a conditional and time-limited pathway that requires confirmatory data within a set period.[19][20]
Provision is not approval
Providing an intervention under a filed plan and holding PMDA marketing approval for a product are separate legal states with separate requirements.[5]
Neither equals proven benefit
Evidence of clinical effectiveness is a third, scientific question. No regenerative medicine product approved specifically for erectile dysfunction was identified in the Japanese regulatory and indexed literature sources reviewed by Japan Medical as of July 28, 2026.[5][3]
A published provision plan records submission and review under the applicable framework. It does not by itself establish clinical effectiveness and should not be described as a government recommendation of the provider.[4]
Risk Classes and Provision Plans
Under the safety act, every intervention is sorted into one of three risk classes, and every provider must file a plan reviewed by a government-certified committee before treating anyone.[4][21]
New-to-humans cells
Cells people have rarely or never received before — for example iPS-cell-derived or gene-modified cells. These face the strictest review, including national-level scrutiny by MHLW.[4]
Somatic stem cells
Interventions using a patient’s own or donor somatic stem cells — the class under which fat-derived stem-cell plans, including those discussed for ED, are generally filed.[4][21]
Minimally processed own cells
Interventions using the patient’s own cells with limited processing, such as certain immune-cell approaches. Review is lighter, but a certified-committee-reviewed plan is still mandatory.[4]
1 · Plan drafted
The provider writes a plan describing the cells, processing method and safety controls.
2 · Committee review
A government-certified committee examines the plan’s safety before any treatment starts.
3 · Filed with MHLW
The reviewed plan is submitted to the health ministry; Class I plans also require national review.[21]
4 · Public disclosure
Plans, committees and processing facilities are published on the MHLW portal for anyone to inspect.[22]
A provider operating under this framework should be able to identify the relevant plan number and risk class. This information can be compared with the MHLW public records, as the next section explains.[22]
How to Use the MHLW Public Records
Japan’s disclosure portal lets anyone check what has actually been filed. The steps below describe how to use it when evaluating any claim about a Japanese provider. This page does not name or assess any specific provider.[22]
1 · Identify the exact intervention nameAsk for the precise name of the cells and procedure, not a marketing label.[22]
2 · Obtain the plan numberThe filed plan carries an identifier that can be searched in the public system.[22]
3 · Identify the risk classConfirm whether the intervention is filed as Class I, II or III.[4]
4 · Search the MHLW portalEnter the plan details on the ministry’s disclosure site and read the actual record.[22]
5 · Compare the institution nameCheck that the name on the record matches the name presented to you.[22]
6 · Review the committeeThe record shows which certified committee reviewed the plan; committees are themselves listed.[22]
7 · Review the processing facilityCell preparation must occur at a disclosed, standards-compliant facility; check that it appears in the system.[4]
8 · Read the consent documentsConsent materials should describe the intervention’s status and uncertainties in plain terms.[10]
9 · Check for changes or ordersPlans can be amended, suspended or terminated; the record reflects the current state.[21]
10 · Record the date of the searchPublic records change over time; note when you checked, and re-check before relying on the result.[22]
How to Recognize Overstated Marketing
Consumer-protection authorities note that health marketing can imply proof through wording alone. The phrases below are common in this market and deserve extra scrutiny when they describe cell-based interventions for ED. Adding hedges such as “may”, “promising” or “preliminary” does not neutralize an implied positive outcome claim.[23][9]
Outcome and certainty claims
Authority and status claims
Pressure and access tactics
Japan Medical Content Method and Update Record
Published and reviewed by Japan Medical.
Japan Medical is the publishing name used by this website. Japan Medical publishes general information based on official public records and indexed research literature. Japan Medical is not a hospital, clinic, laboratory, medical practice or provider-referral service.
Sources reviewed for this page include PubMed, MHLW, PMDA, Japanese Law Translation and ClinicalTrials.gov. Human studies are separated from laboratory and animal research. Controlled evidence is given greater interpretive weight than uncontrolled observations. The page is maintained with reference to the principles described in Google’s guidance on helpful, people-first content and the Search Quality Evaluator Guidelines.[24][25]
Last evidence check: July 28, 2026.
Update record. July 28, 2026: Added the 2026 randomized placebo-controlled study and revised the evidence conclusion.
Frequently Asked Questions
Is regenerative medicine approved specifically for ED?
As of July 28, 2026, Japan Medical did not identify any regenerative medicine product approved specifically for erectile dysfunction in the Japanese regulatory sources and indexed literature reviewed for this page. Cell-based interventions for ED appear in clinical studies and within Japan’s provision framework, neither of which equals product approval. Approval status can change, so readers should confirm current information through PMDA and MHLW sources.[5][21]
What did the strongest controlled study find?
The 2026 randomized, double-blind study assigned 70 men with post-surgery ED to adipose-derived regenerative cells (35) or a placebo (35). At 12 months, the primary IIEF-5 outcome showed no significant between-group difference, and secondary measures did not favor the cells. The authors concluded that the intervention, in its current form, cannot be recommended for that population.[3]
Why did earlier studies report different results?
Earlier studies were small and open-label: participants knew they had received cells, and results were measured as change from each person’s own starting point. Such designs cannot separate the intervention’s effect from expectation, natural fluctuation or other care. A controlled design compares groups directly, which is why its result carries greater interpretive weight.[1][3]
What does an MHLW provision plan mean?
It means a provider’s plan passed safety-process review by a certified committee and was submitted to the health ministry under the applicable law. It records procedural compliance. It does not establish that the intervention works, and it should not be read as a government recommendation of the provider. Plans and committees are listed on the MHLW public portal.[4][22]
Does trial registration mean that an intervention is approved?
No. A registry entry describes a study’s plan, status and sometimes results. Registration is a transparency step, not an evaluation of quality or outcome. An intervention mentioned in a registry may be unproven, unapproved and unavailable outside research. Always separate “studied” from “approved”, and check approval status through regulators such as PMDA.[14][15][5]
Does Japan Medical provide or arrange services?
No. Japan Medical is the publishing name used by this website. It publishes general information based on official public records and indexed research literature. It is not a hospital, clinic, laboratory, medical practice or provider-referral service, and it does not offer assessments, recommendations, referrals or appointments. For personal medical decisions, please consult a qualified physician.
References
About Japan Medical
Published and reviewed by Japan Medical. This material is general information, not medical advice. Last evidence check: July 28, 2026.
Need more context on this page?
Japan Medical accepts general questions about sources, terminology and publicly available information. Japan Medical does not provide personal assessments, provider recommendations, referrals or appointment services. Please do not send medical records, test results or other sensitive health information.
General information enquiries only